title: Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan.
abstract: A nationwide survey of hematopoietic cell transplantation (HCT) was started in Japan in 1991, and the analyzed survey data have been presented as the annual report of the Japan Society for Hematopoietic Cell Transplantation. The 10-year overall survival (OS) rates after HCT for each disease are as follows: acute myelogenous leukemia, 44.2%; acute lymphocytic leukemia, 33.7%; adult T-cell leukemia, 24.6%; chronic myelogenous leukemia, 53.3%; myelodysplastic syndrome, 37.3%; non-Hodgkin's lymphoma, 41.5%; Hodgkin's lymphoma, 50.8%; aplastic anemia, 72.5%; breast cancer, 37.1%; germ cell tumor, 52.6%; and ovarian cancer, 44.2%. The 5-year OS rates for multiple myeloma and lung cancer were 40.6% and 23.6%, respectively. Except in cord blood transplantation, engraftment was accomplished in more than 90% of patients. The respective frequencies of acute graft-versus-host disease (GVHD) and chronic GVHD were 41.1% and 34.9% for related bone marrow transplantation (BMT), 66.8% and 34.5% for unrelated BMT, 52.9% and 36.0% for allogeneic peripheral blood stem cell transplantation, and 53.3% and 32.1% for allogeneic cord blood transplantation. OS for each disease was analyzed by patient age, stem cell source, donor type, disease status, and disease type. These data provide objective and valuable information for hematologists as well as for patients who need HCT.
authors.affiliation: Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. mimamura@med.hokudai.ac.jp
authors.forename: Masahiro
authors.initials: M
authors.lastname: Imamura
authors.forename: Shigetaka
authors.initials: S
authors.lastname: Asano
authors.forename: Mine
authors.initials: M
authors.lastname: Harada
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ikeda
authors.forename: Koji
authors.initials: K
authors.lastname: Kato
authors.forename: Shunichi
authors.initials: S
authors.lastname: Kato
authors.forename: Keisei
authors.initials: K
authors.lastname: Kawa
authors.forename: Seiji
authors.initials: S
authors.lastname: Kojima
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Morishima
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Morishita
authors.forename: Tatsutoshi
authors.initials: T
authors.lastname: Nakahata
authors.forename: Jun
authors.initials: J
authors.lastname: Okamura
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Okamoto
authors.forename: Shintaro
authors.initials: S
authors.lastname: Shiobara
authors.forename: Mitsune
authors.initials: M
authors.lastname: Tanimoto
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tsuchida
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Atsuta
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Junji
authors.initials: J
authors.lastname: Tanaka
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Hamajima
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Kodera
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease; D006402:Hematologic Diseases / Q000453:epidemiology / Q000401:mortality / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000706:statistics & numerical data; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate